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Abstract: Oral anticoagulation is the therapeutic cornerstone in preventing thromboembolic 
risk in both atrial fibrillation (AF) and venous thromboembolism (VTE). After decades of the 
sole therapeutic oral anticoagulation option being warfarin, the introduction of non-vitamin K 
antagonist oral anticoagulants has heralded a new era. Edoxaban is the latest addition to these 
available for clinical use. Edoxaban was as effective and safer than warfarin in preventing 
thromboembolic risk in AF patients. Similarly, edoxaban effectiveness and safety was evident 
when treating VTE patients to prevent recurrent VTE or VTE-related death. Therefore, edoxaban 
represents a valuable alternative in treating thromboembolic risk for AF and VTE patients.
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Introduction
Oral anticoagulation is the therapeutic cornerstone in preventing thromboembolic risk 
in both atrial fibrillation (AF)1,2 and venous thromboembolism (VTE).3 AF is one of 
the most prevalent arrhythmias,4 and is associated with a fivefold increase in stroke 
risk.4 Stroke risk in AF increases with increasing age: for example, in AF patients 
aged 50–59 years, AF-related ischemic stroke incidence is approximately 4.6%, and 
this progressively increases to approximately 20% in patients aged 80–89 years.1 
VTE, whether as deep venous thrombosis or pulmonary embolism, is common, with a 
global incidence of 108 events among whites and 78 events among blacks per 100,000 
person-years in the USA.4,5 Moreover, VTE is associated with a high rate of mortality, 
and heavily affects health care-associated costs.5
Treatment with vitamin K antagonists (VKAs), such as warfarin or acenocoumarol, 
has traditionally been the therapeutic option in AF and VTE patients.3,6 While effec-
tive, VKAs require very close attention to the quality of international normalized ratio 
(INR) control, as reflected by the time in therapeutic range (TTR).6 Indeed, a TTR 
.70% is recommended to achieve best efficacy and safety with VKAs.7,8 However, 
the TTR can be influenced by many common clinical factors, recently described by 
the SAMe-TT
2
R
2
 score.9–12
In the last decade, the development of non-VKA oral anticoagulants (NOACs; 
previously referred to as new or novel oral anticoagulants),13 have changed the 
pharmacological landscape and heralded a new era. In general, the NOACs have 
been proved to be as effective as VKAs,14 and sometimes also superior,15 in reducing 
thromboembolic stroke occurrence in nonvalvular AF (NVAF)16 and in treatment of 
acute and recurrent VTE.17 NOACs are also associated with a reduction in both major 
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(especially intracranial) bleeding and any clinically relevant 
bleeding.17–19
The recent approval of edoxaban20 by the European 
Medicines Agency for the prevention of ischemic stroke 
and systemic thromboembolism in NVAF provides a range 
of therapeutic options with NOACs (apart from VKAs) for 
AF and VTE patients21 (Table 1). The aim of this review is to 
provide a comprehensive overview on the efficacy and safety 
of edoxaban in treating NVAF and VTE patients.
Pharmacological profile of 
edoxaban
Edoxaban is an oral direct factor-Xa inhibitor similar 
to the previously developed molecules rivaroxaban and 
apixaban. Previously known as DU-176b by International 
Union of Pure and Applied Chemistry name N-(5-chloro-
pyridin-2-yl)-N′-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-
2 - (5 -me thy l -4 ,5 ,6 ,7 - t e t r ahyd ro th i azo lo [5 ,4 -c ]
pyridine-2-carboxamido)-cyclohexyl]ethanediamide 
p-toluenesulfonate monohydrate, it was developed from 
the small anticoagulant molecule DX-9065a by Daiichi 
Pharmaceutical (Tokyo, Japan).22 DU-176b is a potent and 
highly selective factor-Xa inhibitor characterized by good 
oral bioavailability compared to its predecessor.22
Both animal and Phase I studies have demonstrated that 
DU-176b is highly effective in factor Xa-inhibition activity 
and reducing clot formation. In rat and monkey models, 
DU-176b showed almost complete inhibition of factor-Xa 
activity and (in particular in monkeys) a rapid onset of 
inhibitory effect.22
In 12 voluntary human subjects, oral administration 
of DU-176b provided significant clot-formation reduc-
tion up to 5 hours postdose, accompanied by parallel and 
consensual reduction in clotting parameters in both arterial 
and venous conditions.23 Moreover, changes in various rou-
tine and specific coagulation assays have also recently been 
described.24
Dose-finding research has shown that edoxaban yields a 
progressive, consistent, and predictable increase in plasma 
concentrations.25 Edoxaban quickly reaches peak plasma 
concentrations in 1.5 hours; its half-life is between 10 and 
14 hours. Oral bioavailability is quite high (more than 62%) 
and factor-Xa inhibition is highly selective, competitive, 
and concentration-dependent.25,26 Plasma concentrations of 
edoxaban are also closely correlated with the suppression 
of other coagulation indices and various platelet-activation 
parameters.26
Given the renal route of elimination, pharmacokinetic 
changes in patients with renal impairment deserve attention. 
In patients with severe renal impairment (creatinine clearance 
15–49 mL/min), a reduced edoxaban dose (15 mg once daily) 
resulted in similar plasma levels and adverse-event rates when 
compared with edoxaban 30 or 60 mg once daily in patients 
with normal or mild renal (dys)function in short-term and 
medium-term follow-up (7 days of treatment).26 In patients 
with end-stage renal disease, hemodialysis treatment has only 
minimal effects on the clearance of edoxaban, so no further 
adjustment is needed.27
Few drug–drug interactions significantly affect edoxaban 
pharmacokinetics. No influence was found with the concomi-
tant use of esomeprazole, atorvastatin, or naproxen.26 Neither 
atorvastatin, enoxaparin, nor low dose aspirin (100 mg) 
influenced edoxaban exposure time.26 While digoxin did 
not influence edoxaban absorption, amiodarone and some 
agents, particularly dronedarone, quinidine, and verapamil 
(all of which are strong P-glycoprotein [P-gp] inhibitors), 
increased edoxaban exposure, requiring dose adjustment.26 
No significant food interactions have been reported.26
Edoxaban in nonvalvular atrial 
fibrillation
Despite some drawbacks and limitations, particularly related 
to an excess of gastrointestinal bleeding (dabigatran 150 mg, 
rivaroxaban, edoxaban), gastrointestinal side effects (dys-
pepsia with dabigatran), and the need of ensuring adequate 
adherence to medication,28,29 NOACs have established 
themselves in current clinical practice for stroke prevention 
in NVAF patients.
Dabigatran,30 rivaroxaban,31 and apixaban15 are part of 
the current NOAC pharmacopoeias available for most of the 
European countries. In Europe, the approval of edoxaban 
Table 1 edoxaban summary
Route of administration Oral
Onset of action Rapid
Bioavailability 62%
Development name DU-176b
iUPAC name N-(5-chloropyridin-2-yl)-N′-[(1S,2R,4S)-
4-(N,N-dimethylcarbamoyl)-2-(5-methyl-
4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-
2-carboxamido)-cyclohexyl]ethanediamide 
p-toluenesulfonate monohydrate
Major indications NvAF, vTe, major orthopedic surgery  
(only in Japan)
Pharmacology description Factor Xa inhibitor
Approval route Approved in the USA, europe, and Japan
Abbreviations: iUPAC, international Union of Pure and Applied Chemistry; NvAF, 
nonvalvular atrial fibrillation; VTE, venous thromboembolism.
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adds another drug choice for patients with NVAF, helping 
physicians identify the best-choice treatment for any single 
patient.
Clinical trials performed thus far have clearly demon-
strated both the efficacy and safety of edoxaban in preventing 
thromboembolism in AF. The pivotal trial for the approval in 
use for treating patients with NVAF was ENGAGE AF-TIMI 
48 (Table 2).20,32 This was a three-arm, randomized, double-
blind, double-dummy trial comparing two dose regimens 
of edoxaban with warfarin. A total of 21,105 patients with 
documented AF within 12 months preceding randomization 
and with a CHADS
2
 score $2 were randomized to receive 
edoxaban 30 mg, edoxaban 60 mg, or dose-adjusted warfarin 
to reach INR values between 2 and 3.
During a median follow-up of 2.8 years, on-treatment 
analysis showed that the primary end point of stroke or 
systemic embolic event (SEE) in the warfarin group, despite 
good anticoagulation control with a median (interquartile 
range) TTR of 68.4% (56.5%–77.4%), was recorded in 232 
patients at an overall rate of 1.50% per year, while patients 
in the high-dose edoxaban group reported 182 events (1.18% 
per year) and patients in the low-dose edoxaban group 
reported 253 primary end-point events (1.61% per year).
The hazard ratio (HR) for primary end point of high-dose 
edoxaban vs warfarin was 0.79 (97.5% confidence interval 
[CI] 0.63–0.99, P,0.001 for noninferiority), while low-
dose edoxaban vs warfarin showed an HR of 1.07 (97.5% 
CI 0.87–1.31, P=0.005 for noninferiority). A superiority 
analysis failed to show a significant difference in the pre-
specified intention-to-treat analysis. Indeed, in this analysis 
the annualized rate of the primary end point was 1.80% in 
the warfarin group compared with 1.57% in the high-dose 
edoxaban group (HR vs warfarin 0.87, 97.5% CI 0.73–1.04; 
P=0.08) and 2.04% in the low-dose edoxaban group (HR vs 
warfarin 1.13, 97.5% CI 0.96–1.34, P=0.10).
For the secondary efficacy outcomes, treatment with high-
dose edoxaban was associated with lower annualized rates of 
death from cardiovascular causes than warfarin: 3.17% with 
warfarin compared with 2.74% with high-dose edoxaban (HR 
0.86, 95% CI 0.77–0.97; P=0.01) and 2.71% with low-dose 
edoxaban (HR 0.85, 95% CI 0.76–0.96; P=0.008). Similar 
data were also reported for all-cause death.
The safety of edoxaban appears to be favorable. Phase 
II clinical trials showed that both low and high edoxaban 
doses had at the very least a similar safety profile to warfarin, 
with no significant increase in major or clinically relevant 
bleeding occurrence.33,34 These data were then reinforced 
with the Phase III ENGAGE AF-TIMI 48 study, where 
major bleeding events were significantly higher in patients 
treated with warfarin (3.43%/year) compared to those on 
high-dose edoxaban (2.75%/year, HR vs warfarin 0.80, 95% 
CI 0.71–0.91; P,0.001) or low-dose edoxaban (1.61%/year, 
HR vs warfarin 0.47, 95% CI 0.41–0.55; P,0.001). Also, the 
rates of life-threatening bleeding, intracranial bleeding, and 
major bleeding plus clinically relevant nonmajor bleeding 
were consistently higher in warfarin-treated patients than in 
either edoxaban dose.20
When the net clinical benefit (NCB) of edoxaban was 
assessed, the rates for the composite net clinical primary 
outcome of death from any cause/stroke/SEE/major bleeding 
were significantly lower with both edoxaban regimens com-
pared to warfarin: 8.11% with warfarin compared with 7.26% 
with high-dose edoxaban (HR 0.89, 95% CI 0.83–0.96; 
P=0.003) and 6.79% with low-dose edoxaban (HR 0.83, 95% 
CI 0.77–0.90; P,0.001). With regard to secondary (death 
from any cause/disabling stroke/life-threatening bleeding) 
and tertiary (stroke/SEE/life-threatening bleeding/death from 
any cause) net clinical outcomes, significantly lower rates 
were found with both edoxaban doses.20
Recently, a large comprehensive meta-analysis, combin-
ing all the edoxaban studies performed in NVAF patients, 
confirmed that edoxaban had the same efficacy and a better 
safety profile than warfarin in treating thromboembolic 
risk.35 In particular, this meta-analysis confirmed that the 
better safety profile was consistent independently of the 
type of bleeding event (major/minor/clinically relevant 
nonmajor bleeding). In the same paper, a direct compari-
son between the two edoxaban regimens showed that both 
low- and high-dose edoxaban were effective in reducing 
both thromboembolic events and all-cause mortality.35 Last, 
Table 2 Phase III randomized clinical trials evaluating edoxaban efficacy and safety
Study Year Study groups Patients Mean FU Primary outcome
eNGAGe AF-TiMi 4820 2009 edoxaban 60 mg OD 
edoxaban 30 mg OD 
Dose-adjusted warfarin (iNR 2–3)
7,035 
7,034 
7,036
2.8 years Stroke/See
Hokusai-vTe46 2013 edoxaban 60 mg OD 
Dose-adjusted warfarin (iNR 2–3)
4,118 
4,122
8.2 months Recurrent 
symptomatic vTe
Abbreviations: FU, follow-up; iNR, international normalized ratio; OD, once daily; See, systemic embolic event; vTe, venous thromboembolism.
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edoxaban 30 mg was associated with a lower incidence of 
all bleeding events.35
A subanalysis of the dose-reduction strategy of ENGAGE 
AF-TIMI 48 was recently published.36 This study showed 
that edoxaban dose adjustment according to concomitant 
clinical factors did not affect efficacy and conferred a better 
safety profile. Indeed, when high-dose edoxaban was con-
sidered, no difference was found in efficacy for the primary 
outcome independently of dose reduction (HR for no dose 
reduction vs warfarin in preventing stroke/SEE 0.78, 95% CI 
0.61–0.99; HR for dose reduction vs warfarin in preventing 
stroke/SEE 0.81, 95% CI 0.58–1.13; P
interaction
=0.85), giving 
even greater safety (HR for no dose reduction vs warfarin 
for major bleeding 0.88, 95% CI 0.76–1.03; HR for dose 
reduction vs warfarin in preventing stroke/SEE 0.63, 95% CI 
0.50–0.81; P
interaction
=0.023). Similar data were found for low-
dose edoxaban. These results were consistent independently 
of the factors used to establish the need for a dose-reduction 
strategy.36
One recent paper investigating the NCB of edoxaban 
through a modeling strategy applied to a large population 
of NVAF patients, according to standard rates of stroke/
SEE and major bleeding, showed that edoxaban had a better 
NCB than warfarin, preventing 0.71 strokes/SEE events per 
100 patient-years for both low-dose and high-dose edoxaban 
compared to 0.26 events per 100 patient-years prevented 
with warfarin.37 Compared to no treatment, both edoxaban 
regimens were found to have a better NCB than warfarin at all 
CHA
2
DS
2
-VASc scores, particularly so in high-risk patients 
(CHA
2
DS
2
-VASc score $2).37
A recent analysis based on indirect comparisons between 
the four NOACs reported that edoxaban 60 mg once daily 
would be as effective as rivaroxaban, apixaban, and dabigatran 
110 mg twice daily, while dabigatran 150 mg twice daily was 
more effective than edoxaban 60 mg once daily.38,39 Indirect 
comparisons on the efficacy and safety of edoxaban vs aspirin 
and no therapy have also been reported.40 However, indirect 
comparisons have many limitations, and given that we have 
four NOACs as well as warfarin, it would be prudent to fit the 
particular NOAC drug to the particular patient profile (and 
vice versa).41 In patients more likely taking once-daily drugs, 
edoxaban could be preferable to rivaroxaban in relation to 
the associated lower bleeding risk with edoxaban.39 Further-
more, in patients needing a reduced-dose regime, edoxaban 
30 mg could be preferred to dabigatran 110 mg twice daily 
or apixaban, given the lowest risk of major bleeding.
One other randomized clinical trial is also ongoing with 
edoxaban in NVAF. The ENSURE-AF (NCT02072434) trial 
aims to evaluate the efficacy and safety of edoxaban in the 
treatment of subjects undergoing elective electric cardiover-
sion.42 The study is a prospective, randomized, open-label, 
blinded, end-point evaluation, parallel-group, Phase IIIB 
study comparing edoxaban with an enoxaparin/warfarin 
regimen in the prophylactic anticoagulant treatment related 
to the cardioversion procedure. The primary end point is a 
composite outcome of stroke, SEE, myocardial infarction, 
and cardiovascular mortality from randomization up to 56 
days after the procedure. The safety end point is the composite 
of major and clinically relevant nonmajor bleeding up to the 
end of anticoagulant treatment after 28 days postprocedure.42 
Results from this trial could be very valuable in targeting 
the clinical role of edoxaban in treating AF patients for this 
specific indication.
In summary, the role of edoxaban in ensuring adequate 
protection for stroke/SEE events and adequate safety in 
NVAF seems to be consistent across various clinical condi-
tions, though real-life data about efficacy and safety are 
still needed, in particular to clarify efficacy and safety in 
various clinical subgroups. Specific safety and efficacy 
data on elderly patients or patients with higher frailties are 
currently still lacking for edoxaban. Until now, virtually all 
data related to edoxaban safety and efficacy have come from 
industry-sponsored trials, and thus independent observational 
data are needed to further confirm the NCB for edoxaban in 
real-world AF populations. Despite being the most recent 
NOAC approved for use in Europe, its properties, such as the 
once-daily regimen, along with the lower bleeding risk and 
consistency of effect in patients with renal impairment when 
a reduced dose is prescribed, could help the decision-making 
process to assign the proper NOAC drug for treatment of the 
right patient.41
Use of edoxaban in symptomatic 
venous thromboembolism 
treatment
Effective treatment for VTE is clearly needed to reduce the 
risk of recurrent VTE and its associated complications.43 
Similarly to AF, treatment of patients with VTE requires 
adequate strategies to balance the risks of VTE recurrence 
and bleeding.3 These new drugs have clearly been demon-
strated to be as effective as warfarin in reducing the risk of 
recurrent VTE.44 Furthermore, NOACs show a better safety 
profile, with the consistently lowest risk of major bleeding 
across all studies.44
The efficacy and safety of edoxaban in the treatment of 
symptomatic VTE were tested in the Hokusai-VTE study45,46 
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(Table 2). Hokusai-VTE was a randomized double-blind, 
double-dummy, parallel-group, noninferiority trial comparing 
edoxaban 60 mg and warfarin after enoxaparin/unfractionated 
heparin lead-in treating patients admitted with symptom-
atic VTE.45 Hokusai-VTE has been the largest study ever 
conducted in this clinical setting, enrolling 8,292 patients 
from January 2001 to October 2012 across 439 centers in 
37 countries.47
Among the total study cohort, 4,921 patients were 
diagnosed with deep venous thrombosis, while 3,319 were 
found to have a pulmonary embolism. The primary effi-
cacy outcome was occurrence of the composite outcome 
of first recurrent VTE/VTE-related death. Treatment with 
edoxaban or warfarin was continued for at least 3 months 
and no more than 12 months, with 40% of the total cohort 
treated up to 12 months. Edoxaban was as effective as 
warfarin in preventing primary outcome occurrence when 
compared with warfarin (HR for edoxaban vs warfarin 
0.89, 95% CI 0.70–1.13; P,0.001 for noninferiority). 
Moreover, edoxaban was safer than warfarin in preventing 
the occurrence of the primary safety outcome of first major 
or clinically relevant nonmajor bleeding (HR for edoxaban 
vs warfarin 0.81, 95% CI 0.71–0.94; P=0.004 for supe-
riority). Similar data were found for the safety outcome 
of clinically relevant nonmajor bleeding (P=0.004) and 
the occurrence of any bleeding (P,0.001). Conversely, 
no significant difference was found for the occurrence of 
major bleeding (HR for edoxaban vs warfarin 0.84, 95% CI 
0.59–1.21; P=0.35). No significant difference was found 
in NCB between edoxaban and warfarin (HR 0.83, 95% 
CI 0.65–1.06; P=0.14).
Subgroup analysis showed no profound difference for 
most subgroup analyses. In the occurrence of the primary 
outcome, only fragile patients were more successfully 
treated than patients with no fragilities (P=0.0408). Safety 
outcomes were significantly reduced in male-subgroup 
patients (P=0.0041) and in Asian patients (P=0.0266). Inter-
estingly, center-level INR TTR for warfarin subjects ,60% 
discriminated the occurrence of primary safety outcome 
(P=0.0175), but not the occurrence of primary efficacy 
outcome (P=0.9136).
A prespecif ied post hoc analysis of patients with 
active/history of cancer also reported that in this large 
subgroup, edoxaban was both effective and safe in pre-
venting recurrent VTE.47 Since the number of patients in 
this specific subgroup was small (n=771), the Hokusai 
VTE–cancer study, a randomized, open-label, clinical trial, 
is ongoing to evaluate whether edoxaban is noninferior 
to low-molecular-weight heparin for treatment of VTE in 
patients with cancer.48
The effect of edoxaban in East Asian patients was 
confirmed by a subgroup analysis, showing lower primary 
outcome occurrence rates in edoxaban than in warfarin (2.8% 
vs 4.5%).49 Edoxaban was also noninferior to warfarin in 
this specific population (HR for primary outcome vs war-
farin 0.64, 95% CI 0.34–1.19; P=0.1601).49 The safer profile 
compared to warfarin was confirmed in East Asian patients, 
with a primary safety outcome that occurred significantly 
less often in the edoxaban group than in warfarin-treated 
patients (9.9% vs 17.3%, respectively, HR 0.56, 95% CI 
0.40–0.78; P,0.001).49
More recently, an indirect comparison between the four 
NOACs on efficacy and safety in preventing recurrent VTE 
was published. No significant differences were found between 
NOACs for the occurrence of the primary outcome of recur-
rent VTE/VTE-related death.44 For the safety outcome of 
major and clinically relevant nonmajor bleeding, apixaban 
was the safest NOAC.44 Despite that, edoxaban was found 
to be the only NOAC to be significantly safer than warfarin 
for the occurrence of fatal bleeding episodes.44 Therefore, 
edoxaban appears to be a valuable alternative in treating 
VTE patients, especially those of East Asian ethnicity and 
those with active cancer.
Reversal strategies and 
management of bleeding 
complications
Since NOACs’ introduction to clinical practice, the most 
relevant concern with them has been the lack of any spe-
cific direct reversal strategy.50 Even if all NOACs have been 
reported as safer than warfarin, given their short half-life, the 
anticoagulant effect is expected to wear off much earlier after 
any bleeding episode compared to warfarin-treated patients. 
Therefore, several attempts have been made to identify bet-
ter strategies to manage bleeding complications,50 which 
have recently been summarized in an European Society of 
Cardiology position paper.51
Of note, specific antidotes have recently been made 
available for dabigatran,52–54 as well as for apixaban and 
rivaroxaban.55 In a recent study among healthy subjects, 
andexanet alpha was able to reverse the anticoagulant effect of 
both apixaban and rivaroxaban in 94% and 96% of subjects, 
respectively.55 Though no specific data have been formally 
published, the use of andexanet alpha in edoxaban-treated 
patients also would seem a promising strategy to reverse the 
latter’s anticoagulant effects.
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Conclusion
NOACs have changed the landscape for thromboprophylaxis 
in AF,13,28,29 and the challenge now is to translate the clini-
cal trials to everyday practice. Gaps in translation remain,28 
as do unanswered questions.56 Particular benefits of NOACs 
are especially evident in Asian patients, who tend to do less 
well on warfarin compared to non-Asians.57 The availability 
of different NOACs enables us to fit the NOAC agent to the 
patient profile, and vice versa.41
On a more specific note, edoxaban represents a valuable 
alternative to warfarin in treating thromboembolic risk for 
AF and VTE patients. Clinical trial data with edoxaban are 
compelling for efficacy and safety. The absence of real-world 
observational data on the efficacy and safety of edoxaban 
in everyday clinical practice is evident, and such data are 
clearly needed.
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